CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS

CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS PHM173A January 2015 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-008-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA), or (+1) 781-489-7301 www.bccresearch.com information@bccresearch.com

TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY OBJECTIVES 2 REASONS FOR DOING THIS STUDY 2 CONTRIBUTIONS OF THE STUDY AND FOR WHOM 2 SCOPE OF THE STUDY 3 METHODOLOGY 3 INFORMATION SOURCES 3 ANALYSTS' CREDENTIALS 3 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH WEBSITE 4 DISCLAIMER 5 CHAPTER 2 EXECUTIVE SUMMARY 7 SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ 8 8 CHAPTER 3 OVERVIEW 10 DEFINITIONS 10 HISTORY OF CANCER AND ITS MANAGEMENT 11 TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT 12 CLASSIFICATION OF CANCERS 13 CLASSIFICATION BY SITE OF ORIGIN 13 CLASSIFICATION BY TISSUE TYPE 13 Carcinoma 14 Adenocarcinoma 14 Squamous Cell Carcinoma 14 Sarcomas 14 Myeloma 14 Leukemias 15 Lymphomas 15 Mixed Types 15 CLASSIFICATION BY GRADE 15 SYMPTOMS OF CANCER 15 LOCAL SYMPTOMS 16 SYSTEMIC SYMPTOMS 16 SYMPTOMS OF THE SPREAD OF CANCER OR METASTASIS 16 RISK FACTORS 16 CANCER-CAUSING AGENTS 16 CHEMICAL CARCINOGENS 17 IONIZING RADIATION 17 VIRAL AND BACTERIAL INFECTIONS 17 GENETIC OR INHERITED CANCERS 17 HORMONAL CHANGES 17 IMMUNE SYSTEM DYSFUNCTION 17

COMMERCIALLY AVAILABLE CANCER VACCINES 18 LIVER CANCER 18 PROSTATE CANCER 20 Radical Retropubic Prostatectomy 20 Laparoscopic Prostatectomy 20 Radical Perineal Prostatectomy 20 Transurethral Resection of the Prostate 20 CERVICAL CANCER 21 PREVALENCE 22 TABLE 2 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS) INCIDENCE AND MORTALITY RATE 23 TABLE 3 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012 23 CANCER STATISTICS BY GEOGRAPHY 23 TABLE 4 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012 TABLE 5 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012 GLOBAL CANCER STATISTICS BY TYPE OF CANCER 24 TABLE 6 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS) TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS) TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS) VARIOUS FORMS OF CANCER STATISTICS BY GEOGRAPHY 26 TABLE 9 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012 TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012 TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012 CANCER AND THE IMMUNE SYSTEM 28 MOLECULAR BIOLOGY OF CANCER 28 CANCER PATHOPHYSIOLOGY 29 ONCOGENES 29 TUMOR SUPPRESSOR GENES 29 PREVENTION OF CANCER 30 MANAGEMENT OF CANCER 30 SURGERY 30 CHEMOTHERAPY 31 RADIATION THERAPY 31 TARGETED THERAPY 31 IMMUNOTHERAPY 31 HORMONAL THERAPY 31 BIOLOGICAL THERAPY 31 CANCER VACCINES 32 CLASSIFICATION OF CANCER VACCINES 32 Preventive (or Prophylactic) Vaccines 32 23 23 24 25 25 26 26 27 28

Therapeutic Vaccines 32 MANUFACTURING/CREATING VACCINES 33 TYPES OF CANCER VACCINES 33 Tumor Cell Vaccines 33 Cancer Stem Cell Vaccines 34 Peptide/Protein Vaccines 34 Antigen Vaccines 34 Anti-idiotype Vaccines 35 Heat Shock Protein Vaccines 35 DNA and Vector-Based Vaccines 35 CHAPTER 4 REGULATORY ASPECTS 38 REGULATORY HISTORY OF APPROVED CANCER VACCINES 38 TABLE 12 REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014 39 RECALLS 40 TABLE 13 PRODUCT RECALLS, JAN. 2010 TO JULY 2014 40 ORPHAN DRUG DESIGNATION 41 TABLE 14 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014 OTHER SIGNIFICANT REGULATORY ASPECTS 42 41 CHAPTER 5 NEW DEVELOPMENTS 44 PROSTATE CANCER 45 TABLE 15 CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.) 45 TABLE 16 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT 46 BREAST CANCER 47 TABLE 17 CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.) 47 TABLE 18 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT 47 CERVICAL CANCER 48 TABLE 19 CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.) 49 TABLE 20 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT 49 LIVER CANCER 50 TABLE 21 CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.) 51 TABLE 22 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT 51 LUNG CANCER 52 TABLE 23 CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.) 52 TABLE 24 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER 53 STOMACH CANCER 53 TABLE 25 CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.) 54 TABLE 26 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT 54 COLORECTAL CANCER 55 TABLE 27 CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.) 55 TABLE 28 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT 56 ESOPHAGEAL CANCER 56 TABLE 29 CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.) 57 TABLE 30 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT 57 CHAPTER 6 MARKET ANALYSIS OF CANCER VACCINES 59

MARKET BY TYPE 59 MARKET OVERVIEW 59 MARKET REVENUES 60 TABLE 31 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 ($ FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 ($ MARKET SHARES 62 TABLE 32 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 62 FIGURE 2 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 62 MARKET BY REGION 62 MARKET OVERVIEW 63 MARKET REVENUES 64 TABLE 33 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ THERAPEUTIC VACCINES 65 Market Overview 66 Market Revenues 68 TABLE 34 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 ($ Market Shares TABLE 35 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 FIGURE 5 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 PROPHYLACTIC VACCINES 71 Market Overview 71 Market Revenues 73 TABLE 36 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ Market Shares 75 TABLE 37 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 FIGURE 7 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 INDUSTRY STRUCTURE 76 PROPHYLACTIC CANCER VACCINES 76 Market Leaders 76 TABLE 38 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013 Market Shares TABLE 39 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 61 61 64 64 69 74 74 75 75

FIGURE 8 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 THERAPEUTIC CANCER VACCINES 78 Market Leader 78 TABLE 40 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013 Market Share 78 TABLE 41 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 FIGURE 9 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 78 79 79 CHAPTER 7 MARKET BY CANCER TYPE 81 GLOBAL MARKET BY CANCER TYPE 81 MARKET REVENUES 81 TABLE 42 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 ($ FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 ($ MARKET SHARES 82 TABLE 43 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 FIGURE 11 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 PROSTATE CANCER 83 Market Overview 83 Market Revenues 84 TABLE 44 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 ($ FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 ($ LIVER CANCER 85 Market Overview 86 Market Revenues 87 TABLE 45 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 ($ FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 ($ CERVICAL CANCER VACCINES 88 Market Overview 88 Market Revenues 89 TABLE 46 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 ($ FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 ($ 82 82 83 83 85 85 87 87 90 90 CHAPTER 8 PATENT ANALYSIS 92 PATENTS BY YEAR 92 TABLE 47 SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.) 92 FIGURE 15 SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.) 93

PATENTS BY TYPE/CATEGORY 93 TABLE 48 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.) 93 FIGURE 16 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.) 93 PATENTS BY COMPANY 94 TABLE 49 U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.) 94 PATENTS BY PATENT HOLDER'S COUNTRY 95 TABLE 50 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.) FIGURE 17 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.) TABLE 51 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 FIGURE 18 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 PATENTS BY ASSIGNEE TYPE 97 TABLE 52 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.) 98 FIGURE 19 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.) 98 95 96 96 97 CHAPTER 9 CURRENT SITUATION 100 FACTORS AFFECTING CANCER VACCINES 100 INCREASING PREVALENCE OF CANCER 100 AGING POPULATION 101 LIFESTYLE CHANGES 101 APPROVALS FOR ADDITIONAL INDICATIONS 101 COMPETITION 101 MANUFACTURERS' STRATEGIES 101 CHAPTER 10 COMPANY PROFILES 104 ADAMIS PHARMACEUTICALS CORP. 104 ADURO BIOTECH INC. 104 ADVANTAGENE INC. 105 ADVAXIS INC. 105 ALPHAVAX HUMAN VACCINES INC. 106 ALTOR BIOSCIENCE CORP. 107 ANTIGEN EXPRESS INC. 108 BAVARIAN NORDIC A/S 108 BELLICUM PHARMACEUTICALS 109 BIOVEST INTERNATIONAL 109 CELLDEX THERAPEUTICS 110 CUREVAC GMBH 110 DENDREON 111 EMD SERONO 111 GALINA BIOPHARMA 112 GENEXINE INC. 112 GLAXOSMITHKLINE 113 GLOBEIMMUNE INC. 113 GRADALIS INC. 114 HEAT BIOLOGICS INC. 114

IMMUNE CELL THERAPY INC. (ICT) 115 IMMUNICUM 115 IMMUNOFRONTIER INC. 116 IMMUNOVATIVE THERAPIES LTD. 116 INOVIO PHARMACEUTICALS 117 ISA PHARMACEUTICALS 117 KAEL-GEMVAX CO. LTD. 118 MERCK & CO. 118 NEWLINK GENETICS CORP. 119 NOVARX CORP. 120 ONCOTHYREON 120 ONCOVIR INC 121 OXFORD BIOMEDICA 121 SOTIO AS 122 UBIVAC LLC 122 VICAL INC. 123 VACCINOGEN INC. 123 VAXON BIOTECH 124 CHAPTER 11 ACRONYMS 126

LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ TABLE 1 HISTORY OF CANCER AND ITS MANAGEMENT 12 TABLE 2 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS) TABLE 3 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012 23 TABLE 4 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012 TABLE 5 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012 TABLE 6 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS) TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS) TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS) TABLE 9 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012 TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012 TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012 TABLE 12 REGULATORY APPROVALS OF CANCER VACCINES, THROUGH JULY 2014 39 TABLE 13 PRODUCT RECALLS, JAN. 2010 TO JULY 2014 40 TABLE 14 SIGNIFICANT ORPHAN DRUG DESIGNATIONS APPROVED FROM JAN. 2010 TO JULY 2014 TABLE 15 CLINICAL TRIALS FOR PROSTATE CANCER VACCINES (NO.) 45 TABLE 16 SIGNIFICANT PROSTATE CANCER VACCINES IN DEVELOPMENT 46 TABLE 17 CLINICAL TRIALS FOR BREAST CANCER VACCINES (NO.) 47 TABLE 18 SIGNIFICANT BREAST CANCER VACCINES IN DEVELOPMENT 47 TABLE 19 CLINICAL TRIALS FOR CERVICAL CANCER VACCINES (NO.) 49 TABLE 20 SIGNIFICANT CERVICAL CANCER VACCINES IN DEVELOPMENT 49 TABLE 21 CLINICAL TRIALS FOR LIVER CANCER VACCINES (NO.) 51 TABLE 22 SIGNIFICANT LIVER CANCER VACCINES IN DEVELOPMENT 51 TABLE 23 CLINICAL TRIALS FOR LUNG CANCER VACCINES (NO.) 52 TABLE 24 SIGNIFICANT VACCINES IN DEVELOPMENT FOR LUNG CANCER 53 TABLE 25 CLINICAL TRIALS FOR STOMACH CANCER VACCINES (NO.) 54 TABLE 26 SIGNIFICANT STOMACH CANCER VACCINES IN DEVELOPMENT 54 TABLE 27 CLINICAL TRIALS FOR COLORECTAL CANCER VACCINES (NO.) 55 TABLE 28 SIGNIFICANT COLORECTAL CANCER VACCINES IN DEVELOPMENT 56 TABLE 29 CLINICAL TRIALS FOR ESOPHAGEAL CANCER VACCINES (NO.) 57 TABLE 30 SIGNIFICANT ESOPHAGEAL CANCER VACCINES IN DEVELOPMENT 57 TABLE 31 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, THROUGH 2019 ($ TABLE 32 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 62 TABLE 33 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 ($ TABLE 34 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ 8 23 23 24 25 25 26 26 27 28 41 61 64 69

TABLE HEADING TABLE 35 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 TABLE 36 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ TABLE 37 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 TABLE 38 LEADING MANUFACTURERS/SUPPLIERS OF PROPHYLACTIC CANCER VACCINES, 2013 TABLE 39 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 TABLE 40 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC CANCER VACCINES, 2013 TABLE 41 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 TABLE 42 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, THROUGH 2019 ($ TABLE 43 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 TABLE 44 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, THROUGH 2019 ($ TABLE 45 GLOBAL MARKET FOR LIVER CANCER VACCINES BY REGION, THROUGH 2019 ($ TABLE 46 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, THROUGH 2019 ($ TABLE 47 SIGNIFICANT PATENTS BY YEAR JAN. 2010 TO JUNE 2014 (NO.) 92 TABLE 48 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.) 93 TABLE 49 U.S. PATENTS BY COMPANY, JAN. 2010 TO JUNE 2014 (NO.) 94 TABLE 50 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.) TABLE 51 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 TABLE 52 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.) 98 74 75 78 79 82 83 85 87 90 95 96

LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY TYPE, 2012-2019 ($ FIGURE 2 GLOBAL MARKET SHARES OF CANCER VACCINES BY TYPE, 2013 62 FIGURE 3 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 ($ FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC CANCER VACCINES BY REGION, 2012-2019 ($ FIGURE 5 GLOBAL MARKET SHARES OF THERAPEUTIC VACCINES BY REGION, 2013 FIGURE 6 GLOBAL MARKET FOR PROPHYLACTIC CANCER VACCINES BY REGION, THROUGH 2019 ($ FIGURE 7 GLOBAL MARKET SHARES OF PROPHYLACTIC VACCINES BY REGION, 2013 FIGURE 8 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF PROPHYLACTIC CANCER VACCINES, 2013 FIGURE 9 GLOBAL MANUFACTURER/SUPPLIER MARKET SHARES OF THERAPEUTIC CANCER VACCINES, 2013 FIGURE 10 GLOBAL MARKET FOR CANCER VACCINES BY TYPE OF CANCER, 2012-2019 ($ FIGURE 11 GLOBAL MARKET SHARES OF CANCER VACCINES BY CANCER TYPE, 2013 FIGURE 12 GLOBAL MARKET FOR PROSTATE CANCER VACCINES, 2012-2019 ($ FIGURE 13 GLOBAL MARKET FOR LIVER CANCER VACCINES, THROUGH 2019 ($ FIGURE 14 GLOBAL MARKET FOR CERVICAL CANCER VACCINES, 2012-2019 ($ FIGURE 15 SIGNIFICANT PATENTS BY YEAR, JAN. 2010 TO JUNE 2014 (NO.) 93 FIGURE 16 PATENTS BY CATEGORY, JAN. 2010 TO JUNE 2014 (NO.) 93 FIGURE 17 U.S. PATENTS BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 (NO.) FIGURE 18 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JAN. 2010 TO JUNE 2014 FIGURE 19 PATENTS BY ASSIGNEE TYPE, JAN. 2010 TO JUNE 2014 (NO.) 98 8 61 64 74 75 79 82 83 85 87 90 96 97